Qizhu Yuling Prescription

PreclinicalSmall molecule

Qizhu Yuling Prescription is one of 3 small molecule programs targeting Esophagus Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophagus CancerUnknown status

Esophagus CancerPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Esophagus Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 1

1 2

Paraplatin

AAvyxa

Phase 1

1 3

Qizhu Yuling Prescription

JJie Li

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophagus Cancer1 trial

Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

Unknown status·JJie Li·N/A·NCT05626309·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Qizhu Yuling Prescription. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Qizhu Yuling Prescription compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Qizhu Yuling Prescription. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jie Li company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJie Li

Qizhu Yuling Prescription

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophagus Cancer1 trial

References

Drug Info

Quick Facts

Related News